Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
bioAffinity Technologies, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
08/14/2023 8-K Quarterly results
Docs: "bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update SAN ANTONIO – bioAffinity Technologies, Inc. , a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and six months ended June 30, 2023, and provided a business update. Highlights from the second quarter of 2023 and subsequent weeks included: Corporate and Commercial Highlights ● The American Medical Association issued a Current Procedural Terminology code for use with CyPath Lung with an effective date of Oct. 1, 2023. CPT codes provide a uniform system to identify medical services and procedures and seek reimbursement from private payers and public health insuranc..."
07/28/2023 8-K Quarterly results
06/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF",
"bioAffinity Technologies, Inc. Amended and Restated 2014 Equity Incentive Plan 1. Purposes. Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are the Employees, Directors and Consultants of the Company and its Affiliates. Available Stock Awards. The purpose of the Plan is to provide a means by which eligible recipients of Stock Awards may be given an opportunity to benefit from increases in value of the Common Stock through the granting of the following Stock Awards: Incentive Stock Options, Nonstatutory Stock Options, and restricted stock awards. General Purpose. The Company, by means of the Plan, seeks to retain the services of the group of persons eligible to receive Stock Awards, to secure and retain the services of new members of this group and to provide i..."
05/15/2023 8-K Quarterly results
Docs: "bioAffinity Technologies Reports First Quarter 2023 Financial Results"
04/25/2023 8-K Quarterly results
04/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies to Ring Nasdaq Closing Bell Today"
03/28/2023 8-K Quarterly results
03/24/2023 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023"
03/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023"
02/13/2023 8-K Quarterly results
01/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research"
01/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Tiberend Strategic Advisors, Inc."
12/15/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench"
12/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting"
11/08/2022 8-K Other Events, Financial Statements and Exhibits
Docs: "bioAffinity Technologies to Report Third Quarter 2022 Financial Results"
10/25/2022 8-K Quarterly results
10/12/2022 8-K Other Events, Financial Statements and Exhibits
Docs: "Tiberend Strategic Advisors, Inc."
09/28/2022 8-K Other Events, Financial Statements and Exhibits
Docs: "bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M"
09/06/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and between the Company and WallachBeth Capital, LLC",
"Form of Tradeable Common Stock Purchase Warrant, issued as part of the Units sold in the Offering pursuant to the Underwriting Agreement",
"Form of Non-tradeable Common Stock Purchase Warrant, issued as part of the Units sold in the Offering pursuant to the Underwriting Agreement",
"Warrant Agent Agreement, by and between the Company and VStock Transfer, LLC for the Warrants issued as part of the Units sold in the Offering pursuant to the Underwriting Agreement",
"bioAffinity Technologies Announces Pricing of IPO",
"bioAffinity Technologies, Inc. Announces Closing of $7.8 million Initial Public Offering"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy